Zacks.com on MSN3d
Here's Why you Should Retain Nevro Stock in Your Portfolio NowNVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
Nevro’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 29.98%. Market Expansion Into SI Joint Fusion: Nevro's expansion into ...
L’azienda, specializzata nello sviluppo di terapie cellulari per il cancro e altre malattie incurabili, si sta preparando per il previsto ... ha recentemente ricoperto il ruolo di CFO presso Nevro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback